特発性肺線維症（IPF）の世界市場 - 薬剤タイプ別、エンドユーザー別、地域別、国別の分析（2021年版）。COVID-19の影響を受けた市場インサイト、パイプライン、予測（2021年～2026年）

Global Idiopathic Pulmonary Fibrosis (IPF) Market – Analysis By Drug Type, End User, By Region, By Country (2021 Edition): Market Insights, Pipeline and Forecast with Impact of COVID-19 (2021-2026)

エグゼクティブサマリー Azoth Analytics社の調査レポートによると、特発性肺線維症の世界市場は、2020年に3271.3百万米ドルとなる堅調な成長を見せ、北米が地域別市場シェアをリードすると予測されています。... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Azoth Analytics アーゾスアナリティクス	2021年12月31日	US$2,400 シングルユーザーライセンスライセンス・価格情報・注文方法はこちら	220	英語

サマリー

エグゼクティブサマリー

Azoth Analytics社の調査レポートによると、特発性肺線維症の世界市場は、2020年に3271.3百万米ドルとなる堅調な成長を見せ、北米が地域別市場シェアをリードすると予測されています。

近年のIPF市場の成長の主な要因は、高価格帯のピルフェニドン（エスブリエット）およびニンテダニブ（オフェブ）ブランドが、適応外薬理療法や非薬理療法を優先して使用されるようになったことにあります。これらの薬剤が承認される以前は、一般的な治療法としてエビデンスに基づくガイドラインで否定的な勧告がなされているにもかかわらず、安価なコルチコステロイドと免疫抑制剤がIPFの治療に使用されていました。

世界の特発性肺線維症市場の成長を促す主な要因としては、線維性疾患の有病率の上昇や老年人口の増加などが挙げられます。また、費用対効果の高い薬剤に対する需要の急増や、先進的な治療オプションの導入が市場成長を後押ししています。さらに、ライフスタイルの変化やニコチン製品の消費量の増加が、市場成長の推進力となっています。さらに、タバコや煙草の喫煙は、IPFの発症の最も一般的な原因と考えられています。これに伴い、IPFの効果的な管理戦略に関する大衆の健康意識が高まっていることも、市場の成長に好影響を与えています。

さらに、新薬の登場やIPFの診断・治療法の進歩も、成長を促す要因となっています。これに加えて、広範な研究開発活動や医療インフラの改善も、市場を牽引すると予想されるその他の要因の1つです。

また、IPFの患者さんには、薬物療法だけでなく、さまざまな非薬物療法も行われています。最も使用されている非薬物療法は、肺移植、機械的換気、酸素療法、肺のリハビリテーションです。一般に、IPFの治療法は、患者の症状、病期、患者の全身状態によって大きく左右されます。

報告書の範囲

- 当レポートでは、特発性肺線維症市場の過去期間（2016年～2020年）および予測期間（2021年～2026年）の分析をご紹介しています。

- 当レポートでは、特発性肺線維症市場を金額（百万米ドル）別に分析しています。

- 当レポートでは、特発性肺線維症市場を薬剤タイプ別（ニンテダニブ、ピルフェニドン、その他）に分析しています。

- 特発性肺線維症市場をエンドユーザー別（病院・クリニック、学術・研究機関、その他）に分析した報告書です。

- 世界の特発性肺線維症市場は地域別（北米、欧州、アジア太平洋）に分析されています。

- 特発性肺線維症の世界市場を国別に分析（米国、カナダ、ドイツ、フランス、英国、スペイン、イタリア、中国、日本、インド）。

- 市場の魅力は、地域別、薬物クラス別、エンドユーザー別で提示されています。

- また、業界の主な機会、トレンド、ドライバー、課題についても分析されています。

- 競合他社の動向、戦略、M&A、新製品開発などを追跡しています。

- 本レポートで分析対象とする企業は、AbbVie Inc.、Bristol-Myers Squibb、F. Hoffman-La Roche, Ltd.、Boehringer Ingelheim、Merck KGaA、Gilead Sciences、Liminal Biosciences、Cipla、Galapagos NV、FibroGen、Medicinova Inc、MediGen、MediGen, Inc.

主な対象読者

- 製薬会社、ヘルスケア企業

- コンサルティング・アドバイザリーファーム

- 政府・政策担当者

- 規制当局

ページTOPに戻る

1. Report Scope and Methodology

1.1 Scope of the Report

1.2 Research Methodology

1.3 Executive Summary

2. Strategic Recommendations

3. Idiopathic Pulmonary Fibrosis Market: Product Outlook

4. Global Idiopathic Pulmonary Fibrosis Market: Sizing and Forecast

4.1 Global Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026

4.2 Impact of COVID-19 on Global Idiopathic Pulmonary Fibrosis Market

5. Global Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User

5.1 Competitive Scenario of Global Idiopathic Pulmonary Fibrosis Market: By Drug Type

5.1.1 Nintedanib - Market Size and Forecast (2016-2026)

5.1.2 Pirfenidone - Market Size and Forecast (2016-2026)

5.1.3 Others - Market Size and Forecast (2016-2026)

5.2 Competitive Scenario of Global Idiopathic Pulmonary Fibrosis Market: By End User

5.2.1 Hospitals and Clinics - Market Size and Forecast (2016-2026)

5.2.2 Academics and Research Organization - Market Size and Forecast (2016-2026)

5.2.3 Others - Market Size and Forecast (2016-2026)

6. Global Idiopathic Pulmonary Fibrosis Market: Regional Analysis

6.1 Competitive Scenario of Global Idiopathic Pulmonary Fibrosis Market: By Region

7. North America Idiopathic Pulmonary Fibrosis Market: An Analysis (2016-2026)

7.1 North America Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

7.2 North America Idiopathic Pulmonary Fibrosis Market - Prominent Companies

7.3 Market Segmentation By Drug Type (Nintedanib, Pirfenidone and Others)

7.4 Market Segmentation By End User (Hospitals and Clinics, Academics and Research Organization and Others)

7.5 North America Idiopathic Pulmonary Fibrosis Market: Country Analysis

7.6 Market Opportunity Chart of North America Idiopathic Pulmonary Fibrosis Market - By Country, By Value, 2026

7.7 Competitive Scenario of North America Idiopathic Pulmonary Fibrosis Market: By Country

7.8 United States Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

7.9 United States Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)

7.10 Canada Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

7.11 Canada Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)

8. Europe Idiopathic Pulmonary Fibrosis Market: An Analysis (2016-2026)

8.1 Europe Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

8.2 Europe Idiopathic Pulmonary Fibrosis Market - Prominent Companies

8.3 Market Segmentation By Drug Type (Nintedanib, Pirfenidone, Others)

8.4 Market Segmentation By End User (Hospitals and Clinics, Academics and Research Organization, Others)

8.5 Europe Idiopathic Pulmonary Fibrosis Market: Country Analysis

8.6 Market Opportunity Chart of Europe Idiopathic Pulmonary Fibrosis Market - By Country, By Value, 2026

8.7 Competitive Scenario of Europe Idiopathic Pulmonary Fibrosis Market: By Country

8.8 Germany Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

8.9 Germany Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)

8.10 United Kingdom Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

8.11 United Kingdom Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)

8.12 France Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

8.13 France Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)

8.14 Italy Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

8.15 Italy Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)

8.16 Spain Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

8.17 Spain Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)

9. Asia Pacific Idiopathic Pulmonary Fibrosis Market: An Analysis (2016-2026)

9.1 Asia Pacific Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

9.2 Asia Pacific Idiopathic Pulmonary Fibrosis Market - Prominent Companies

9.3 Market Segmentation By Drug Type (Nintedanib, Pirfenidone, Others)

9.4 Market Segmentation By End User (Hospitals and Clinics, Academics and Research Organization, Others)

9.5 Asia Pacific Idiopathic Pulmonary Fibrosis Market: Country Analysis

9.6 Market Opportunity Chart of Asia Pacific Idiopathic Pulmonary Fibrosis Market - By Country, By Value, 2026

9.7 Competitive Scenario of Asia Pacific Idiopathic Pulmonary Fibrosis Market: By Country

9.8 China Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

9.9 China Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)

9.10 Japan Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

9.11 Japan Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)

9.12 India Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

9.13 India Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)

10. Global Idiopathic Pulmonary Fibrosis Market Dynamics

10.1 Drivers

10.2 Restraints

10.3 Trends

11. Market Attractiveness

11.1 Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market - By Drug Type, 2026

11.2 Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market - By End User, 2026

11.3 Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market - By Region, 2026

12. Competitive Landscape

12.1 Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies

12.2 Market Share Analysis

13. Company Analysis

13.1 AbbVie Inc.

13.2 Bristol-Myers Squibb

13.3 F. Hoffman-La Roche Ltd.

13.4 Boehringer Ingelheim

13.5 Merck KGaA

13.6 Gilead Sciences

13.7 Liminal Biosciences

13.8 Cipla

13.9 Galapagos NV

13.10 FibroGen

13.11 Medicinova Inc.

List of Figures

Figure 1: Global Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 2: Global Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 3: GDP per Capita Growth (annual %), 2015-2019

Figure 4: World Population 65 Years & Above (% of Total), 2015-2019

Figure 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 6: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)

Figure 7: Global IPF - Number of Drugs by Phase

Figure 8: Global Idiopathic Pulmonary Fibrosis Market- By Drug Type Market Share, 2020 & 2026

Figure 9: Global Idiopathic Pulmonary Fibrosis Market- By Nintedanib, By Value (USD Million), 2016-2026

Figure 10: Global Idiopathic Pulmonary Fibrosis Market- By Pirfenidone, By Value (USD Million), 2016-2026

Figure 11: Global Idiopathic Pulmonary Fibrosis Market- By Others, By Value (USD Million), 2016-2026

Figure 12: Global Idiopathic Pulmonary Fibrosis Market- By End User Market Share, 2020 & 2026

Figure 13: Global Idiopathic Pulmonary Fibrosis Market- By Hospitals and Clinics, By Value (USD Million), 2016-2026

Figure 14: Global Idiopathic Pulmonary Fibrosis Market- By Academics and Research Organization, By Value (USD Million), 2016-2026

Figure 15: Global Idiopathic Pulmonary Fibrosis Market- By Others, By Value (USD Million), 2016-2026

Figure 16: Global Idiopathic Pulmonary Fibrosis Market- By Region Market Share, 2020 & 2026

Figure 17: North America Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 18: North America Current health expenditure(% of GDP)2014-2018

Figure 19: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 20: North America Population ages 65 and above (% of total Population), 2016-2020

Figure 21: North America Idiopathic Pulmonary Fibrosis company market share (%), 2020

Figure 22: North America Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 23: North America Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 24: Market Opportunity Chart of North America Idiopathic Pulmonary Fibrosis Market- By Country, By Value (Year 2016-2026)

Figure 25: North America Idiopathic Pulmonary Fibrosis Market- By Country Market Share, 2020 & 2026

Figure 26: United States Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 27: United States Distribution of Diagnosed IPF Patients, 2020

Figure 28: United States Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 29: United States Population aged 65 and above (% of total Population), 2016-2020

Figure 30: United States Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 31: United States Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 32: Canada Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 33: Canada Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 34: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 35: Canada Population aged 65 and above (% of total Population), 2016-2020

Figure 36: Canada Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 37: Canada Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 38: Europe Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 39: Europe Distribution of Diagnosed IPF Patients, 2020

Figure 40: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 41: European Countries Population ages 65 and above (% of total Population), 2020

Figure 42: Europe Idiopathic Pulmonary Fibrosis company market share (%), 2020

Figure 43: Europe Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 44: Europe Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 45: Market Opportunity Chart of Europe Idiopathic Pulmonary Fibrosis Market- By Country, By Value (Year 2016-2026)

Figure 46: Europe Idiopathic Pulmonary Fibrosis Market- By Country Market Share, 2020 & 2026

Figure 47: Germany Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 48: Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 49: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 50: Germany Urban population growth,(Annual %) 2015-2020 (In %)

Figure 51: Germany Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 52: Germany Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 53: United Kingdom Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 54: United Kingdom Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 55: United Kingdom Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 56: United Kingdom Population ages 65 and above (% of total Population), 2016-20

Figure 57: United Kingdom Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 58: United Kingdom Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 59: France Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 60: France Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 61: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 62: France Population ages 65 and above (% of total Population), 2016-20

Figure 63: France Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 64: France Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 65: Italy Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 66: Italy Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 67: Italy Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 68: Italy Population ages 65 and above (% of total Population), 2016-20

Figure 69: Italy Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 70: Italy Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 71: Spain Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 72: Spain Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 73: Spain Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 74: Spain Urban population Growth (Annual %), 2016-2020 (In %)

Figure 75: Spain Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 76: Spain Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 77: Asia Pacific Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 78: Asia Pacific Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 79: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 80: Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020

Figure 81: Asia Pacific Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 82: Asia Pacific Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 83: Market Opportunity Chart of APAC Idiopathic Pulmonary Fibrosis Market- By Country, By Value (Year-2026)

Figure 84: APAC Idiopathic Pulmonary Fibrosis Market- By Country Market Share, 2020 & 2026

Figure 85: China Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 86: China Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 87: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 88: China Population ages 65 and above (% of total Population), 2016-20

Figure 89: China Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 90: China Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 91: Japan Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 92: Japan Europe Distribution of Diagnosed IPF Patients, 2020

Figure 93: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)

Figure 94: Japan Population ages 65 and above (% of total Population), 2016-20

Figure 95: Japan Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 96: Japan Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 97: India Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 98: India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 99: India Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 100: India Population ages 65 and above (% of total Population), 2016-20

Figure 101: India Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 102: India Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 103: Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market- By Drug Type (Year-2016-2026)

Figure 104: Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market- By End User (Year 2016-2026)

Figure 105: Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market- By Region (Year 2016-2026)

Figure 106: Global Idiopathic Pulmonary Fibrosis company market share

Figure 107: AbbVie Inc. Annual Sales Revenue (USD Million), 2016-2020

Figure 108: AbbVie Inc. Net Income (USD Million), 2016-2020

Figure 109: AbbVie Inc. Sales Revenue Split, By Business Segment (%), FY2020

Figure 110: AbbVie Inc. Sales Revenue Split, By Geography Segment (%), FY2020

Figure 111: Bristol-Myers Squibb Sales Revenues, 2016-2020 (USD Million)

Figure 112: Bristol-Myers Squibb Net Income, 2016-2020 (USD Million)

Figure 113: Bristol-Myers Squibb Sales Revenue Split, By Business Segment (%), FY2020

Figure 114: Bristol-Myers Squibb Sales Revenue Split, By Geography Segment (%), FY2020

Figure 115: F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)

Figure 116: F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)

Figure 117: F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020

Figure 118: F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020

Figure 119: Boehringer Ingelheim Revenues, 2016-2020 (USD Million)

Figure 120: Boehringer Ingelheim Net Income/Loss, 2016-2020 (USD Million)

Figure 121: Boehringer Ingelheim Sales Revenue Split, By Business Segment (%), FY2020

Figure 122: Boehringer Ingelheim Sales Revenue Split, By Geography Segment (%), FY2020

Figure 123: Merck KGaA Sales Revenues, 2016-2020 (USD Million)

Figure 124: Merck KGaA Gross Profit, 2016-2020 (USD Million)

Figure 125: Merck KGaA Sales Revenue Split, By Business Segment (%), FY2020

Figure 126: Merck KGaA Sales Revenue Split, By Geography Segment (%), FY2020

Figure 127: Gilead Sciences, Revenue, 2016-2020 (USD Million)

Figure 128: Gilead Sciences, Net Income 2016-2020 (USD Million)

Figure 129: Gilead Sciences, Revenue, By Business Segment (%), FY2020

Figure 130: Gilead Sciences Revenue, By Geographical Segment (%), FY2020

Figure 131: Liminal Biosciences, Revenue, 2016-2020 (USD Million)

Figure 132: Liminal Biosciences, Net Loss 2016-2020 (USD Million)

Figure 133: Liminal Biosciences, Revenue, By Business Segment (%), FY2020

Figure 134: Liminal Biosciences Revenue, By Geographical Segment (%), FY2020

Figure 135: Cipla Sales Revenues, 2016-2020 (USD Million)

Figure 136: Cipla sales Revenues, By Business Segment (%), FY2020

Figure 137: Cipla sales Revenue, By Geographical Segment (%), FY2020

Figure 138: Galapagos NV Annual Sales Revenue (USD Million), 2016-2020

Figure 139: Galapagos NV sales Revenue, By Geographical Segment (%), FY2020

Figure 140: FibroGen, Revenue, 2016-2020 (USD Million)

Figure 141: FibroGen, Net Loss 2016-2020 (USD Million)

Figure 142: MediciNova, Inc., Total Operating Expenses, 2015-2019 (USD Million)

Figure 143: MediciNova Inc., Net Loss 2015-2019 (USD Million)

List of Tables

Table A Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies

Table B Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies

Table C Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies

Table D Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies - Vicore Pharma

Table E Deals in IPF and severe cough

ページTOPに戻る

Table of Contents

Summary

Executive Summary

According to Azoth Analytics research report, the global Idiopathic Pulmonary Fibrosis Market is projected to display robust growth valued at USD 3271.3 Million in the year 2020 with North America leading the regional market share.

The primary driver of growth in the IPF market in recent years has been an increased use of the high-priced Pirfenidone (Esbriet) and Nintedanib (Ofev) brands in favour of off-label pharmacological therapies and non-pharmacological treatments. Prior to the approval of these drugs, cheap corticosteroids and immunosuppressant's were used to treat IPF despite negative recommendations in evidence-based guidelines for general treatment.

The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include a rise in the prevalence of fibrotic disease and an increase in the geriatric population. In addition, a surge in demand for cost-effective drugs and the introduction of advanced treatment options propel market growth. Furthermore, changing lifestyle patterns and increasing consumption of nicotine products is providing a thrust to the market growth. Moreover, smoking tobacco and cigarettes are considered the most common cause for the development of IPF. In line with this, increasing health consciousness among the masses regarding the effective management strategies of IPF is also favouring the growth of the market.

Additionally, the advent of novel medicines and advancements in the IPF diagnostic and treatment methods, are acting as other growth-inducing factors. This, along with extensive research and development (R&D) activities and improvements in the healthcare infrastructure, represents some of the other factors anticipated to drive the market.

Moreover, to pharmacological treatments, various non-pharmacological treatments are also used for IPF patients. The most used non-pharmacological treatments are lung transplantations, mechanical ventilation, oxygen therapy, and pulmonary rehabilitation. In general, the treatment approach in IPF is largely dependent on a patient’s symptoms, the stage of the disease, and a patient’s overall health.

Scope of the Report

• The report presents the analysis of the Idiopathic Pulmonary Fibrosis market for the historical period of 2016-2020 and the forecast period of 2021-2026.

• The report analyses the Idiopathic Pulmonary Fibrosis Market by Value (USD Million).

• The report analyses the Idiopathic Pulmonary Fibrosis Market by Drug Type (Nintedanib, Pirfenidone, Others).

• The report analyses the Idiopathic Pulmonary Fibrosis Market by End User (Hospital & Clinics, Academic and Research Organizations, Others).

• The Global Idiopathic Pulmonary Fibrosis Market has been analysed By Region (North America, Europe, Asia Pacific).

• The Global Idiopathic Pulmonary Fibrosis Market has been analysed By Country (United States, Canada, Germany, France, United Kingdom, Spain, Italy, China, Japan, India).

• The attractiveness of the market has been presented by region, by Drug Class and by End User.

• Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development.

• The companies analysed in the report include AbbVie Inc., Bristol-Myers Squibb, F. Hoffman-La Roche, Ltd., Boehringer Ingelheim, Merck KGaA, Gilead Sciences, Liminal Biosciences, Cipla, Galapagos NV, FibroGen, Medicinova Inc.

Key Target Audience

• Pharmaceutical and Healthcare Companies

• Consulting and Advisory Firms

• Government and Policy Makers

• Regulatory Authorities

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（その他）の最新刊レポート

Azoth Analytics 社の最新刊レポート

本レポートと同じKEY WORD（covid19）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

特発性肺線維症（IPF）の世界市場 - 薬剤タイプ別、エンドユーザー別、地域別、国別の分析（2021年版）。COVID-19の影響を受けた市場インサイト、パイプライン、予測（2021年～2026年）

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（その他）の最新刊レポート

Azoth Analytics 社の最新刊レポート

本レポートと同じKEY WORD（covid19）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?